^
    7d
    Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=720, Not yet recruiting, Dana-Farber Cancer Institute
    New P3 trial
    |
    TP53 (Tumor protein P53)
    |
    clonoSEQ®
    |
    bortezomib • dexamethasone • iberdomide (CC-220) • Lynozyfic (linvoseltamab-gcpt) • Sarclisa subcutaneous (isatuximab subcutaneous) • captisol-enabled melphalan
    28d
    Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=62, Recruiting, Natalie Callander | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Xpovio (selinexor) • carfilzomib • Sarclisa subcutaneous (isatuximab subcutaneous) • dexamethasone injection
    1m
    ISASOCUT: Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=74, Active, not recruiting, Poitiers University Hospital | Trial primary completion date: Jul 2026 --> Mar 2026
    Trial primary completion date
    |
    lenalidomide • bortezomib • dexamethasone • Sarclisa subcutaneous (isatuximab subcutaneous)
    1m
    IZALCO: A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=118, Active, not recruiting, Sanofi | N=55 --> 118
    Enrollment change
    |
    carfilzomib • dexamethasone • Sarclisa subcutaneous (isatuximab subcutaneous) • dexamethasone injection
    3ms
    Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=62, Not yet recruiting, Natalie Callander
    New P1/2 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 deletion
    |
    Xpovio (selinexor) • carfilzomib • Sarclisa subcutaneous (isatuximab subcutaneous) • dexamethasone injection
    3ms
    ELISA in Relapsed/Refractory MM (clinicaltrials.gov)
    P2, N=30, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Elrexfio (elranatamab-bcmm) • Sarclisa subcutaneous (isatuximab subcutaneous)
    4ms
    Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=514, Completed, University of Heidelberg Medical Center | Active, not recruiting --> Completed | Trial completion date: Jul 2026 --> Jan 2026 | Trial primary completion date: Jul 2025 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date • Head-to-Head
    |
    lenalidomide • bortezomib • dexamethasone • melphalan • Sarclisa subcutaneous (isatuximab subcutaneous)
    6ms
    IZALCO: A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carfilzomib • dexamethasone • Sarclisa subcutaneous (isatuximab subcutaneous) • dexamethasone injection
    12ms
    IZALCO: A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=118, Recruiting, Sanofi | Active, not recruiting --> Recruiting | N=74 --> 118 | Trial completion date: Mar 2027 --> May 2028 | Trial primary completion date: Nov 2024 --> Feb 2026
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    carfilzomib • dexamethasone • Sarclisa subcutaneous (isatuximab subcutaneous) • dexamethasone injection
    12ms
    CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies. (PubMed, Blood Neoplasia)
    Additionally, AAVS1KO/CD38-CAR NK cells were capable of targeting CD38 without experiencing fratricide and have a similar enhanced metabolic activity via the inhibitory activity of the cis-acting isatuximab-based scFv. Finally, we report fratricide-resistant CD38-CAR NK cells with enhanced metabolism and cytotoxicity toward CD38+ hematologic malignancies, further increased by combination treatment with ATRA.
    Journal • IO biomarker
    |
    CD38 (CD38 Molecule)
    |
    Sarclisa subcutaneous (isatuximab subcutaneous)
    over1year
    SubQSA: A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=64, Recruiting, Sanofi | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carfilzomib • dexamethasone • Sarclisa subcutaneous (isatuximab subcutaneous)
    over1year
    Lenalidomide, Bortezomib and Dexamethasone Induction Therapy with Either Intravenous or Subcutaneous Isatuximab in Patients with Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=514, Active, not recruiting, University of Heidelberg Medical Center | Recruiting --> Active, not recruiting
    Enrollment closed • Head-to-Head
    |
    lenalidomide • bortezomib • dexamethasone • melphalan • Sarclisa subcutaneous (isatuximab subcutaneous)